FDA Clears AstraZeneca Breast Cancer Regimen on Early Detection
WILMINGTON, DE — AstraZeneca’s (NYSE: AZN) ETCAMAH (camizestrant) combination won accelerated U.S. approval for certain advanced breast cancer patients whose tumors develop an ESR1 mutation during first-line therapy, allowing treatment …
FDA Clears AstraZeneca Breast Cancer Regimen on Early Detection Read More